Insulin glargine: a basal insulin for the management of diabetes

References

• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med.329, 977–986 (1993).
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet352, 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standard of medical care in diabetes. Diabetes Care1(Suppl. 30), S4–S31 (2007).
   Google Scholar
• International Diabetes Federation: Global Guidelines for Type 2 Diabetes. Clinical Guidelines Task Force (2005).
   Google Scholar
• Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care29, 1963–1972 (2006).
   PubMed Web of Science ®Google Scholar
• Lantus® prescribing information. August (2004).
   Google Scholar
• Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care23, 644–649 (2000).
   PubMed Web of Science ®Google Scholar
• Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia48, 1988–1995 (2005).
   PubMed Web of Science ®Google Scholar
• Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes49, 2142–2148 (2000).
   PubMed Web of Science ®Google Scholar
• Heise T, Nosek L, Ronn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with Type 1 diabetes. Diabetes53, 1614–1620 (2004).
   PubMed Web of Science ®Google Scholar
• Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Insulin detemir and insulin glargine: similar time-action profiles in subjects with Type 2 diabetes. Am. Diabetes Assoc. (2006) (Abstract 325-OR).
   Google Scholar
• Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care23, 813–819 (2000).
   PubMed Web of Science ®Google Scholar
• Heise T, Bott S, Rave K, Dressler A, Rosskamp R, Heinemann L. No evidence for accumulation of insulin glargine (LANTUS®): a multiple injection study in patients with Type 1 diabetes. Diabet. Med.19, 490–495 (2002).
   PubMed Web of Science ®Google Scholar
• Luzio SD, Beck P, Owens DR. Comparison of the subcutaneous absorption of insulin glargine (Lantus®) and NPH insulin in patients with Type 2 diabetes. Horm. Metab. Res.35, 434–438 (2003).
   PubMed Web of Science ®Google Scholar
• Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with Type 1 diabetes. Diabetes Metab. Res. Rev.21, 545–553 (2005).
   PubMed Web of Science ®Google Scholar
• Hershon KS, Blevins TC. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with Type 1 diabetes. Endocr. Pract.10, 10–17 (2004).
   PubMedGoogle Scholar
• Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for Type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care23, 639–643 (2000).
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in Type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care23, 1130–1136 (2000).
   PubMed Web of Science ®Google Scholar
• Eliaschewitz FG, Calvo C, Valbuena H et al. Therapy in Type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch. Med. Res.37, 495–501 (2006).
   PubMed Web of Science ®Google Scholar
• Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with Type 2 diabetes. Horm. Metab. Res.35, 189–196 (2003).
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of Type 2 diabetic patients. Diabetes Care26, 3080–3086 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in Type 2 diabetes. Diabetes Care28, 950–955 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in Type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care24, 631–636 (2001).
   PubMed Web of Science ®Google Scholar
• Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with Type 2 diabetes. A randomized, controlled trial. Ann. Intern. Med.138, 952–959 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Davies M, Home P, Larsen J, Tamer S, Schernthaner G. Insulin detemir added to oral anti-diabetic drugs in Type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain. Am. Diabetes Assoc. (2006) (Abstract 555-P).
   Google Scholar
• Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with Type 1 diabetes mellitus. J. Pediatr. Endocrinol. Metab.15, 369–376 (2002).
   PubMedGoogle Scholar
• Colino E, Lopez-Capape M, Golmayo L, Alvarez MA, Alonso M, Barrio R. Therapy with insulin glargine (Lantus®) in toddlers, children and adolescents with Type 1 diabetes. Diabetes Res. Clin. Pract.70, 1–7 (2005).
   PubMed Web of Science ®Google Scholar
• Hamann A, Matthaei S, Rosak C, Silvestre L. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with Type 1 diabetes. Diabetes Care26, 1738–1744 (2003).
   PubMed Web of Science ®Google Scholar
• Standl E, Maxeiner S, Raptis S, Karimi-Anderesi Z, Schweitzer MA. Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care28, 419–420 (2005).
   PubMed Web of Science ®Google Scholar
• Kennedy L, Herman WH, Strange P, Harris A. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with Type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1c) trial. Diabetes Care29, 1–8 (2006).
   PubMed Web of Science ®Google Scholar
• Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of glycemic control in subjects with poorly controlled Type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care28, 1282–1288 (2005).
   PubMed Web of Science ®Google Scholar
• Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of Type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care26, 881–885 (2003).
   PubMed Web of Science ®Google Scholar
• Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr. Pract.12(Suppl. 1), 42–46 (2006).
   PubMedGoogle Scholar
• Kazda C, Hulstrunk H, Helsberg K, Langer F, Forst T, Hanefeld M. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with Type 2 diabetes beginning insulin therapy. J. Diabetes Complicat.20, 145–152 (2006).
   PubMed Web of Science ®Google Scholar
• Bretzel RG LT, for the Apollo Study Group. Diabetologia49(Suppl. 1), 145 (2006) (Abstract).
   Google Scholar
• Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in Type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care28, 260–265 (2005).
   PubMed Web of Science ®Google Scholar
• Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for Type 2 diabetes. Diabetes Care28, 254–259 (2005).
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled Type 2 diabetes: a randomized trial. Ann. Intern. Med.143, 559–569 (2005).
   PubMed Web of Science ®Google Scholar
• Mucha GT, Merkel S, Thomas W, Bantle JP. Fasting and insulin glargine in individuals with Type 1 diabetes. Diabetes Care27, 1209–1210 (2004).
   PubMedGoogle Scholar
• Clement S, Braithwaite SS, Magee MF et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care27, 553–591 (2004).
   PubMed Web of Science ®Google Scholar
• Leahy JL. Insulin management of diabetic patients on general medical and surgical floors. Endocr. Pract.12(Suppl. 3), 86–90 (2006).
   PubMedGoogle Scholar
• Devlin JT, Hothersall L, Wilkis JL. Use of insulin glargine during pregnancy in a Type 1 diabetic woman. Diabetes Care25, 1095–1096 (2002).
   PubMed Web of Science ®Google Scholar
• Dolci M, Mori M, Baccetti F. Use of glargine insulin before and during pregnancy in a woman with Type 1 diabetes and Addison’s Disease. Diabetes Care28, 2084–2085 (2005).
   PubMedGoogle Scholar
• Torlone E, Gennarini A, Ricci NB, Bolli GB. Successful use of insulin glargine during entire pregnancy until delivery in six Type 1 diabetic women. Eur. J. Obstet. Gynecol. Reprod. Biol.132(2), 238-239 (2006).
   PubMedGoogle Scholar
• Graves DE, White JC, Kirk JK. The use of insulin glargine with gestational diabetes mellitus. Diabetes Care29, 471–472 (2006).
   PubMed Web of Science ®Google Scholar
• McEwan P, Poole CD, Tetlow T, Holmes P, Currie CJ. Evaluation of the cost–effectiveness of insulin glargine versus NPH insulin for the treatment of Type 1 diabetes in the UK. Curr. Med. Res. Opin.23(Suppl. 1), 7–19 (2007).
   PubMed Web of Science ®Google Scholar
• McEwan P, Poole CD, Tetlow T, Holmes P, Currie CJ. Evaluation of the cost–effectiveness of insulin glargine versus NPH insulin for the treatment of Type 1 diabetes in the UK. Curr. Med. Res. Opin.23(Suppl. 1), 21–31 (2007).
   Web of Science ®Google Scholar
• Currie CJ, Poole CD, Tetlow T, Holmes P, McEwan P. The outcome of care in people with Type 1 and Type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr. Med. Res. Opin.23(Suppl. 1), 33–39 (2007).
   Web of Science ®Google Scholar
• Currie CJ, McEwan P, Poole C et al. Comments on long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naive Type 2 diabetes patients: cost–effectiveness analysis in the UK setting. Curr. Med. Res. Opin.22, 967–969 (2006).
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Palmer AJ, Erny-Albrecht KM et al. Cost–effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. Adv. Ther.23, 191–207 (2006).
   PubMed Web of Science ®Google Scholar
• Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Diabet. Med.18, 619–625 (2001).
   PubMed Web of Science ®Google Scholar
• Houlden R, Ross S, Harris S, Yale JF, Sauriol L, Gerstein HC. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study. Diabetes Res. Clin. Pract. (2007) (In Press).
   PubMedGoogle Scholar
• Group HSI. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. Diabet. Med.20, 545–551 (2003).
   PubMed Web of Science ®Google Scholar
• Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with Type 1 diabetes. Diabetes Care23, 1666–1671 (2000).
   PubMed Web of Science ®Google Scholar
• Ciardullo AV, Bacchelli M, Daghio MM, Carapezzi C. Effectiveness and safety of insulin glargine in the therapy of complicated or secondary diabetes: clinical audit. Acta. Diabetol.43, 57–60 (2006).
   PubMedGoogle Scholar
• Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet. Med.23, 879–886 (2006).
   PubMed Web of Science ®Google Scholar
• Albright ES, Desmond R, Bell DS. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in Type 1 diabetic patients using basal/bolus therapy. Diabetes Care27, 632–633 (2004).
   PubMed Web of Science ®Google Scholar
• Sheehan JP. Fasting hyperglycemia: etiology, diagnosis, and treatment. Diabetes Technol. Ther.6, 525–533 (2004).
   PubMedGoogle Scholar
• Jungmann E. Intensified insulin therapy of Type 2 diabetes mellitus: insulin glargine vs. insulin detemir as basal insulin. Am. Diabetes Assoc. (2006) (Abstract 496-P).
   Google Scholar